Inventor · disambiguated record

Naoka Hironiwa

Also filed as: HIRONIWA NAOKA

24 granted patents·25 pending applications·140 citations·filing 2011–2025

95Inventor score

Technology areasC07K C12N A61K A61P C40B

Files withCHUGAI PHARMACEUTICAL CO LTD48 IGAWA TOMOYUKI1

Top patents by PatentIndex Score

49 records

0195US11154615B2Library of antigen-binding molecules including modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Oct 26, 2021·8 cites·11 claims
0295US9975966B2Cytotoxicity-inducing theraputic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted May 22, 2018·25 cites·10 claims
0394US11260125B2Anti-IL31RA antibody-containing formulationsCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 1, 2022·4 cites·28 claims
0494US11168139B2Antigen-binding domain, and polypeptide including conveying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Nov 9, 2021·7 cites·8 claims
0594US11142563B2Antigen-binding molecule containing modified Fc regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Oct 12, 2021·18 cites·53 claims
0693US11723976B2Methods of administering anti-IL31A antibody-containing formulationsCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Aug 15, 2023·2 cites·30 claims
0793US11001643B2Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted May 11, 2021·9 cites·34 claims
0892US11739149B2Antigen-binding molecule containing modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Aug 29, 2023·5 cites·18 claims
0992US10024867B2Ion concentration-dependent binding molecule libraryCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Jul 17, 2018·24 cites·18 claims
1091US12234573B2Library of antigen-binding molecules including modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Feb 25, 2025·1 cites·12 claims
1191US11891434B2Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Feb 6, 2024·6 cites·32 claims
1290US11932697B2Antigen-binding domain, and polypeptide including conveying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Granted Mar 19, 2024·1 cites·16 claims
1390US11820793B2Drug containing carrier into cell for forming immune complexCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Nov 21, 2023·5 cites·25 claims
1490US11485790B2Immunoactivating antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Nov 1, 2022·6 cites·8 claims
1589US12171830B2Anti-IL-31RA antibody-containing formulationsCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Dec 24, 2024·1 cites·24 claims
1688US11952422B2Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137CHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Apr 9, 2024·4 cites·15 claims
1787US11851476B2Antigen-binding molecule having regulated conjugation between heavy-chain and light-chainCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Granted Dec 26, 2023·5 cites·27 claims
1885US12479916B2Antigen-binding molecule containing modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Granted Nov 25, 2025·0 cites·19 claims
1985US11400157B2Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusionCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Aug 2, 2022·3 cites·12 claims
2085US2025250362A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
2183US12304960B2Anti-CD137 antigen-binding molecule and utilization thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted May 20, 2025·3 cites·27 claims
2283US12030955B2Polypeptide including antigen-binding domain and carrying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Jul 9, 2024·2 cites·19 claims
2383US2025064930A1Anti-il-31ra antibody-containing formulationsCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
2480US2024150476A1Antigen-binding domain, and polypeptide including conveying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
2578US2024158482A1Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
2674US2025026852A1Polypeptide including antigen-binding domain and carrying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
2773US12077577B2Polypeptide comprising aggrecan binding domain and carrying moietyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 3, 2024·1 cites·27 claims
2872US12377143B2Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusionCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Granted Aug 5, 2025·0 cites·8 claims
2972US2022187308A1Ion concentration-dependent binding molecule libraryCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
3072US2021230311A1Cytotoxicity-inducing therapeutic agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
3169US2025154689A1Library of Antigen-Binding Molecules Including Modified Antibody Variable RegionCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
3269US2023151112A1Immunoactivating antigen-binding moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
3367US2024190960A1Antigen-binding molecule and combinationCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
3467US2024270846A1Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137CHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
3563US11243210B2Ion concentration-dependent binding molecule libraryCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Feb 8, 2022·0 cites·11 claims
3662US2024270806A1Protease-activated cytokineCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
3762US2016280787A1Antigen-binding molecule containing modified antibody variable regionCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Application pending·0 cites
3862US2025388689A1Anti-cd137 antigen-binding molecule and utilization thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
3959US2020087380A1Antigen-binding molecule having regulated conjugation between heavy-chain and light-chainCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
4058US2024343771A1Protease-mediated target specific cytokine delivery using fusion polypeptideCHUGAI PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
4157US2021122812A1Antigen-binding molecule for eliminating aggregated antigensCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
4255US2014234340A1Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedlyIGAWA TOMOYUKI·Filed 2011·Application pending·0 cites
4354US2020399373A1Antigen-binding molecule and combinationCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
4453US2022315909A1Protease substrate, and polypeptide including protease cleavage sequenceCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
4553US2015056182A1Drug containing carrier into cell for forming immune complexCHUGAI PHARMACEUTICAL CO LTD·Filed 2012·Application pending·0 cites
4649US2015353630A1Antigen-binding molecule for eliminating aggregated antigensCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Application pending·0 cites
4745US2021155701A1Polypeptide comprising il-1r1 binding domain and carrying moietyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
4845US2021253672A1Ligand-binding molecule containing single domain antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
4941US2021238308A1Antigen-binding molecule showing changed half-life in cytoplasmCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites

Join the waitlist — get patent alerts

Get an alert when Naoka Hironiwa files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →